MitoRx Therapeutics
CompanyUnited Kingdom
MitoRx Therapeutics develops 2 assets, the furthest preclinical (MTRX31 in metabolically unhealthy obesity). Mostly small molecule acting on oxidative phosphorylation and Mitochondrial biogenesis (PGC-1α); based in the United Kingdom.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- £9.9m
- 0
- Trials
- 1
- Signal
Pipeline
2Restores mitochondrial health by rebalancing fat and carbohydrate oxidation toward carbohydrate oxidation.
Preclinical, Small molecule, Oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α), metabolically unhealthy obesity, obesity
Orally optimized derivative of MTRX31
Preclinical, Small molecule, metabolically unhealthy obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Funding rounds and grants11
- People24
- Signals4
- Similar companies6